Epix Medical has granted Bracco Imaging a worldwide, nonexclusive, royalty-bearing license for the use of certain patents. The $10 million deal covers patents related to Bracco’s Multihance, which is used to image the liver and central nervous
Epix Medical has granted Bracco Imaging a worldwide, nonexclusive, royalty-bearing license for the use of certain patents. The $10 million deal covers patents related to Bracco’s Multihance, which is used to image the liver and central nervous system. In May 2000, Epix granted Schering a worldwide, nonexclusive, royalty-bearing license for the sale of Eovist, an investigational MRI contrast agent for liver imaging. The patents are owned by the Massachusetts General Hospital and licensed exclusively to Epix, which will receive upfront payments made up of a license fee, royalties on past sales, prepayment of future royalties, and a contingent license fee based on marketing approval of Multihance in the U.S.
Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.
Study Shows Enhanced Diagnosis of Coronary Artery Stenosis with Photon-Counting CTA
July 10th 2025In a new study comparing standard resolution and ultra-high resolution modes for patients undergoing coronary CTA with photon-counting detector CT, researchers found that segment-level sensitivity and accuracy rates for diagnosing coronary artery stenosis were consistently > 89.6 percent.
FDA Expands Approval of MRI-Guided Ultrasound Treatment for Patients with Parkinson’s Disease
July 9th 2025For patients with advanced Parkinson’s disease, the expanded FDA approval of the Exablate Neuro platform allows for the use of MRI-guided focused ultrasound in performing staged bilateral pallidothalamic tractotomy.